Australian University Rankings Guide

Disability and Rehabilitation Assistive Technology (ERA Journal)

Disability and Rehabilitation Assistive Technology is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

Disability and Rehabilitation Assistive Technology issns are issn1: 1748-3107 issn2: 1748-3115.

The fields covered by Disability and Rehabilitation Assistive Technology as part of the evaluation of Australian university research excellence are:

Clinical Sciences Research Rankings (Sub-Field)

Public Health and Health Services Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Clinical Sciences field include:

- Aerospace and environmental medicine
- American Journal of Electroneurodiagnostic Technology
- American Journal of Rhinology and Allergy
- Annales de Chirurgie Plastique et Esthetique
- Clinical Genetics: an international journal of genetics and molecular medicine
- Current Cardiology Reviews
- Dermatologic Therapy
- Epidemics: the journal of infectious disease dynamics
- International Journal of Colorectal Disease: clinical and molecular gastroenterology and surgery
- Journal of Clinical Neuromuscular Disease
- Journal of Crohn's and Colitis
- Journal of Cystic Fibrosis
- Journal of Nuclear Medicine
- Journal of the American Academy of Orthopaedic Surgeons
- Pulmonary Pharmacology and Therapeutics


ERA Research Rankings Submenu


- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List



Latest News and Updates:


- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4